OTC Markets EXMKT - Delayed Quote USD

RenovaCare, Inc. (RCAR)

Compare
0.0001
0.0000
(0.00%)
As of April 3 at 4:00:00 PM EDT. Market Open.
Loading Chart for RCAR
  • Previous Close 0.0002
  • Open 0.0002
  • Bid --
  • Ask --
  • Day's Range 0.0002 - 0.0002
  • 52 Week Range 0.0001 - 0.0300
  • Volume 3,335
  • Avg. Volume 0
  • Market Cap (intraday) 8,735
  • Beta (5Y Monthly) -96.17
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0600
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

RenovaCare, Inc., a development-stage biotech and medical device company, focuses on the research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. It is developing CellMist System, a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to the treatment area. RenovaCare, Inc. has a strategic collaboration StemCell Systems GmbH for isolating and spraying self-donated stem cells to regenerate tissues and organs. The company was formerly known as Janus Resources, Inc. and changed its name RenovaCare, Inc.,to RenovaCare, Inc. in January 2014. RenovaCare, Inc. was incorporated in 1983 and is based in Scottsdale, Arizona.

www.renovacareinc.com

1

Full Time Employees

December 31

Fiscal Year Ends

Recent News: RCAR

View More

Performance Overview: RCAR

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

RCAR
0.00%
S&P 500 (^GSPC)
11.96%

1-Year Return

RCAR
0.00%
S&P 500 (^GSPC)
0.60%

3-Year Return

RCAR
99.96%
S&P 500 (^GSPC)
12.99%

5-Year Return

RCAR
99.99%
S&P 500 (^GSPC)
108.06%

Compare To: RCAR

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: RCAR

View More

Valuation Measures

Annual
As of 10/17/2024
  • Market Cap

    8.73k

  • Enterprise Value

    708.00k

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -103.99%

  • Return on Equity (ttm)

    -568.90%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -5.74M

  • Diluted EPS (ttm)

    -0.0600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    100.74k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -1.21M

Research Analysis: RCAR

View More

Company Insights: RCAR

Research Reports: RCAR

View More

People Also Watch